Sucampo, Takeda enter constipation drug deal
Sucampo (R&D oriented biotech focusing on under-treated niche diseases) and Takeda will collaborate on the development of lubiprostone (SPI-0211), a late-stage compound in Sucampo's pipeline for indications in chronic constipation (completed Phase III) and constipation-predominant irritable bowel syndrome (completed Phase II).
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.